This Week's Headlines: May 17, 2021
Click Here to Manage Email Alerts
This week, a monoclonal antibody cocktail cut COVID-19 hospitalization and death by 70% in an outpatient setting; removing race correction in lung function tests shows more severe disease in Black patients; gefapixant reduces chronic cough frequency in a large pooled analysis; daily probiotics reduced upper respiratory tract infection symptoms; and moderate alcohol intake lowers stress-related brain activity and may reduce CVD risk.
Read the full coverage here:
Monoclonal antibody cocktail cut COVID-19 hospitalization, death by 70% in outpatient setting
Removing race correction in lung function tests shows more severe disease in Black patients
Gefapixant reduces chronic cough frequency in large pooled analysis
Probiotics, reduction in upper respiratory tract infection symptoms
Moderate alcohol intake lowers stress-related brain activity, may reduce CVD risk
References:
Mezue K, et al. Highlighted original research: Prevention and health promotion and the year in review. Presented at: American College of Cardiology Scientific Session; May 15-17, 2021 (virtual meeting).
Moffett AT, et al. Impact of race, ethnicity and social determinants on individuals with lung diseases. Presented at: American Thoracic Society International Conference; May 14-19, 2021 (virtual meeting).
Mullish B, et al. Abstract 739. Presented at: Digestive Disease Week; May 21-23, 2021; Virtual.
Philley J, et al. Breaking news: Clinical trial results in pulmonary medicine. Presented at: American Thoracic Society International Conference; May 14-19, 2021 (virtual meeting).
Smith J, et al. Assessment and treatment of cough and chronic dyspnea. Presented at: American Thoracic Society International Conference; May 14-19, 2021 (virtual meeting).
Collapse
Click Here to Manage Email Alerts
